The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer
The androgen receptor co‐activator CREB (cAMP‐response element binding protein)‐binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. The aim of the present study was to investigate the regulation of CBP expression by st...
Gespeichert in:
| Veröffentlicht in: | The Journal of pathology 2004-10, Vol.204 (2), p.159-166 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 166 |
|---|---|
| container_issue | 2 |
| container_start_page | 159 |
| container_title | The Journal of pathology |
| container_volume | 204 |
| creator | Comuzzi, Barbara Nemes, Constanze Schmidt, Stefan Jasarevic, Zerina Lodde, Michele Pycha, Armin Bartsch, Georg Offner, Felix Culig, Zoran Hobisch, Alfred |
| description | The androgen receptor co‐activator CREB (cAMP‐response element binding protein)‐binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. The aim of the present study was to investigate the regulation of CBP expression by steroid and peptide hormones in prostate cancer. For this purpose, LNCaP cells were treated with the synthetic androgen methyltrienolone (R1881), epidermal growth factor, insulin‐like growth factor‐I or interleukin‐6 (IL‐6). CBP protein and mRNA expression were studied by western blotting and real‐time PCR, respectively. CBP expression was also investigated in tissue specimens obtained from 26 patients with therapy‐resistant carcinoma of the prostate. In LNCaP cells, CBP protein was down‐regulated by R1881 or IL‐6. The non‐steroidal anti‐androgen bicalutamide antagonized the effects of R1881 and the Janus kinase inhibitor AG 490 reversed the effects of IL‐6. In contrast, neither R1881 nor IL‐6 caused any effect on CBP expression in the PC‐3 cell line. In LNCaP cells, the inhibition of CBP expression by R1881 or IL‐6 was also observed at the mRNA level. CBP protein was detected in all 26 specimens by immunohistochemistry. The results suggest that up‐regulation of CBP during androgen ablation may be relevant to the failure of endocrine therapy in patients with prostate carcinoma. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/path.1609 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66905713</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66905713</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4809-aafd74c277984c33f3b553b44ff0f7a9d40158d0d4bc315b47ca9656f8de9f683</originalsourceid><addsrcrecordid>eNp1kM1uEzEUhS0EomlhwQug2YDUxbR2_DdethE0oAoKBJDYWB7_JAZnZrBnmuYNeGw8yoisWNn3-jvnXh8AXiB4gSCcX3aq31wgBsUjMENQsFJUgj0Gs_w2LzFB_AScpvQTQigEpU_BCaKYV6TiM_BntbGFakxs17YpotW269tY6LZUuvf3aiwW13eFT8XQldGuh6B6awrXhtDufLM-ine-35iodiqMvVGx8etN2Bf2oYs2pazyTaHMvWp0vnexTX32KvRYx2fgiVMh2efTeQa-vn2zWizL24837xZXt6UmFRSlUs5woueci4pojB2uKcU1Ic5Bx5UwBCJaGWhIrTGiNeFaCUaZq4wVjlX4DLw--Ob5vwebern1SdsQVGPbIUnGBKQc4QyeH0CdF03ROtlFv1VxLxGUY-xyjF2OsWf25WQ61FtrjuSUcwZeTYBKWgUX8599OnIMEQrn43aXB27ng93_f6K8u1otp9HlQeFTbx_-KVT8JRnHnMrvH27k5_c_lp_INyi_4L_wp6vA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66905713</pqid></control><display><type>article</type><title>The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Comuzzi, Barbara ; Nemes, Constanze ; Schmidt, Stefan ; Jasarevic, Zerina ; Lodde, Michele ; Pycha, Armin ; Bartsch, Georg ; Offner, Felix ; Culig, Zoran ; Hobisch, Alfred</creator><creatorcontrib>Comuzzi, Barbara ; Nemes, Constanze ; Schmidt, Stefan ; Jasarevic, Zerina ; Lodde, Michele ; Pycha, Armin ; Bartsch, Georg ; Offner, Felix ; Culig, Zoran ; Hobisch, Alfred</creatorcontrib><description>The androgen receptor co‐activator CREB (cAMP‐response element binding protein)‐binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. The aim of the present study was to investigate the regulation of CBP expression by steroid and peptide hormones in prostate cancer. For this purpose, LNCaP cells were treated with the synthetic androgen methyltrienolone (R1881), epidermal growth factor, insulin‐like growth factor‐I or interleukin‐6 (IL‐6). CBP protein and mRNA expression were studied by western blotting and real‐time PCR, respectively. CBP expression was also investigated in tissue specimens obtained from 26 patients with therapy‐resistant carcinoma of the prostate. In LNCaP cells, CBP protein was down‐regulated by R1881 or IL‐6. The non‐steroidal anti‐androgen bicalutamide antagonized the effects of R1881 and the Janus kinase inhibitor AG 490 reversed the effects of IL‐6. In contrast, neither R1881 nor IL‐6 caused any effect on CBP expression in the PC‐3 cell line. In LNCaP cells, the inhibition of CBP expression by R1881 or IL‐6 was also observed at the mRNA level. CBP protein was detected in all 26 specimens by immunohistochemistry. The results suggest that up‐regulation of CBP during androgen ablation may be relevant to the failure of endocrine therapy in patients with prostate carcinoma. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.1609</identifier><identifier>PMID: 15378487</identifier><identifier>CODEN: JPTLAS</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Aged ; Aged, 80 and over ; androgen ; Androgen Antagonists - pharmacology ; androgen receptor ; Anilides - pharmacology ; Biological and medical sciences ; CBP ; Cell Line, Tumor ; co-activators ; CREB-Binding Protein ; Down-Regulation - genetics ; endocrine therapy ; Enzyme Inhibitors - pharmacology ; Epidermal Growth Factor - pharmacology ; Gene Expression Regulation, Neoplastic - genetics ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry - methods ; Insulin-Like Growth Factor I - pharmacology ; Interleukin-6 ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Male genital diseases ; Medical sciences ; Metribolone - pharmacology ; Nephrology. Urinary tract diseases ; Nitriles ; Nuclear Proteins - genetics ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; prostate cancer ; prostate cancer cell line ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - genetics ; Receptors, Androgen - genetics ; RNA, Messenger - analysis ; RNA, Neoplasm - analysis ; Tosyl Compounds ; Trans-Activators - genetics ; Tumors ; Tumors of the urinary system ; Tyrphostins - pharmacology ; Up-Regulation - genetics ; Urinary tract. Prostate gland</subject><ispartof>The Journal of pathology, 2004-10, Vol.204 (2), p.159-166</ispartof><rights>Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4809-aafd74c277984c33f3b553b44ff0f7a9d40158d0d4bc315b47ca9656f8de9f683</citedby><cites>FETCH-LOGICAL-c4809-aafd74c277984c33f3b553b44ff0f7a9d40158d0d4bc315b47ca9656f8de9f683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpath.1609$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpath.1609$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16145028$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15378487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Comuzzi, Barbara</creatorcontrib><creatorcontrib>Nemes, Constanze</creatorcontrib><creatorcontrib>Schmidt, Stefan</creatorcontrib><creatorcontrib>Jasarevic, Zerina</creatorcontrib><creatorcontrib>Lodde, Michele</creatorcontrib><creatorcontrib>Pycha, Armin</creatorcontrib><creatorcontrib>Bartsch, Georg</creatorcontrib><creatorcontrib>Offner, Felix</creatorcontrib><creatorcontrib>Culig, Zoran</creatorcontrib><creatorcontrib>Hobisch, Alfred</creatorcontrib><title>The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer</title><title>The Journal of pathology</title><addtitle>J. Pathol</addtitle><description>The androgen receptor co‐activator CREB (cAMP‐response element binding protein)‐binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. The aim of the present study was to investigate the regulation of CBP expression by steroid and peptide hormones in prostate cancer. For this purpose, LNCaP cells were treated with the synthetic androgen methyltrienolone (R1881), epidermal growth factor, insulin‐like growth factor‐I or interleukin‐6 (IL‐6). CBP protein and mRNA expression were studied by western blotting and real‐time PCR, respectively. CBP expression was also investigated in tissue specimens obtained from 26 patients with therapy‐resistant carcinoma of the prostate. In LNCaP cells, CBP protein was down‐regulated by R1881 or IL‐6. The non‐steroidal anti‐androgen bicalutamide antagonized the effects of R1881 and the Janus kinase inhibitor AG 490 reversed the effects of IL‐6. In contrast, neither R1881 nor IL‐6 caused any effect on CBP expression in the PC‐3 cell line. In LNCaP cells, the inhibition of CBP expression by R1881 or IL‐6 was also observed at the mRNA level. CBP protein was detected in all 26 specimens by immunohistochemistry. The results suggest that up‐regulation of CBP during androgen ablation may be relevant to the failure of endocrine therapy in patients with prostate carcinoma. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>androgen</subject><subject>Androgen Antagonists - pharmacology</subject><subject>androgen receptor</subject><subject>Anilides - pharmacology</subject><subject>Biological and medical sciences</subject><subject>CBP</subject><subject>Cell Line, Tumor</subject><subject>co-activators</subject><subject>CREB-Binding Protein</subject><subject>Down-Regulation - genetics</subject><subject>endocrine therapy</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Epidermal Growth Factor - pharmacology</subject><subject>Gene Expression Regulation, Neoplastic - genetics</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Insulin-Like Growth Factor I - pharmacology</subject><subject>Interleukin-6</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Metribolone - pharmacology</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nitriles</subject><subject>Nuclear Proteins - genetics</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>prostate cancer</subject><subject>prostate cancer cell line</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Receptors, Androgen - genetics</subject><subject>RNA, Messenger - analysis</subject><subject>RNA, Neoplasm - analysis</subject><subject>Tosyl Compounds</subject><subject>Trans-Activators - genetics</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Tyrphostins - pharmacology</subject><subject>Up-Regulation - genetics</subject><subject>Urinary tract. Prostate gland</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1uEzEUhS0EomlhwQug2YDUxbR2_DdethE0oAoKBJDYWB7_JAZnZrBnmuYNeGw8yoisWNn3-jvnXh8AXiB4gSCcX3aq31wgBsUjMENQsFJUgj0Gs_w2LzFB_AScpvQTQigEpU_BCaKYV6TiM_BntbGFakxs17YpotW269tY6LZUuvf3aiwW13eFT8XQldGuh6B6awrXhtDufLM-ine-35iodiqMvVGx8etN2Bf2oYs2pazyTaHMvWp0vnexTX32KvRYx2fgiVMh2efTeQa-vn2zWizL24837xZXt6UmFRSlUs5woueci4pojB2uKcU1Ic5Bx5UwBCJaGWhIrTGiNeFaCUaZq4wVjlX4DLw--Ob5vwebern1SdsQVGPbIUnGBKQc4QyeH0CdF03ROtlFv1VxLxGUY-xyjF2OsWf25WQ61FtrjuSUcwZeTYBKWgUX8599OnIMEQrn43aXB27ng93_f6K8u1otp9HlQeFTbx_-KVT8JRnHnMrvH27k5_c_lp_INyi_4L_wp6vA</recordid><startdate>200410</startdate><enddate>200410</enddate><creator>Comuzzi, Barbara</creator><creator>Nemes, Constanze</creator><creator>Schmidt, Stefan</creator><creator>Jasarevic, Zerina</creator><creator>Lodde, Michele</creator><creator>Pycha, Armin</creator><creator>Bartsch, Georg</creator><creator>Offner, Felix</creator><creator>Culig, Zoran</creator><creator>Hobisch, Alfred</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200410</creationdate><title>The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer</title><author>Comuzzi, Barbara ; Nemes, Constanze ; Schmidt, Stefan ; Jasarevic, Zerina ; Lodde, Michele ; Pycha, Armin ; Bartsch, Georg ; Offner, Felix ; Culig, Zoran ; Hobisch, Alfred</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4809-aafd74c277984c33f3b553b44ff0f7a9d40158d0d4bc315b47ca9656f8de9f683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>androgen</topic><topic>Androgen Antagonists - pharmacology</topic><topic>androgen receptor</topic><topic>Anilides - pharmacology</topic><topic>Biological and medical sciences</topic><topic>CBP</topic><topic>Cell Line, Tumor</topic><topic>co-activators</topic><topic>CREB-Binding Protein</topic><topic>Down-Regulation - genetics</topic><topic>endocrine therapy</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Epidermal Growth Factor - pharmacology</topic><topic>Gene Expression Regulation, Neoplastic - genetics</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Insulin-Like Growth Factor I - pharmacology</topic><topic>Interleukin-6</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Metribolone - pharmacology</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nitriles</topic><topic>Nuclear Proteins - genetics</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>prostate cancer</topic><topic>prostate cancer cell line</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Receptors, Androgen - genetics</topic><topic>RNA, Messenger - analysis</topic><topic>RNA, Neoplasm - analysis</topic><topic>Tosyl Compounds</topic><topic>Trans-Activators - genetics</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Tyrphostins - pharmacology</topic><topic>Up-Regulation - genetics</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Comuzzi, Barbara</creatorcontrib><creatorcontrib>Nemes, Constanze</creatorcontrib><creatorcontrib>Schmidt, Stefan</creatorcontrib><creatorcontrib>Jasarevic, Zerina</creatorcontrib><creatorcontrib>Lodde, Michele</creatorcontrib><creatorcontrib>Pycha, Armin</creatorcontrib><creatorcontrib>Bartsch, Georg</creatorcontrib><creatorcontrib>Offner, Felix</creatorcontrib><creatorcontrib>Culig, Zoran</creatorcontrib><creatorcontrib>Hobisch, Alfred</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Comuzzi, Barbara</au><au>Nemes, Constanze</au><au>Schmidt, Stefan</au><au>Jasarevic, Zerina</au><au>Lodde, Michele</au><au>Pycha, Armin</au><au>Bartsch, Georg</au><au>Offner, Felix</au><au>Culig, Zoran</au><au>Hobisch, Alfred</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J. Pathol</addtitle><date>2004-10</date><risdate>2004</risdate><volume>204</volume><issue>2</issue><spage>159</spage><epage>166</epage><pages>159-166</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><coden>JPTLAS</coden><abstract>The androgen receptor co‐activator CREB (cAMP‐response element binding protein)‐binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. The aim of the present study was to investigate the regulation of CBP expression by steroid and peptide hormones in prostate cancer. For this purpose, LNCaP cells were treated with the synthetic androgen methyltrienolone (R1881), epidermal growth factor, insulin‐like growth factor‐I or interleukin‐6 (IL‐6). CBP protein and mRNA expression were studied by western blotting and real‐time PCR, respectively. CBP expression was also investigated in tissue specimens obtained from 26 patients with therapy‐resistant carcinoma of the prostate. In LNCaP cells, CBP protein was down‐regulated by R1881 or IL‐6. The non‐steroidal anti‐androgen bicalutamide antagonized the effects of R1881 and the Janus kinase inhibitor AG 490 reversed the effects of IL‐6. In contrast, neither R1881 nor IL‐6 caused any effect on CBP expression in the PC‐3 cell line. In LNCaP cells, the inhibition of CBP expression by R1881 or IL‐6 was also observed at the mRNA level. CBP protein was detected in all 26 specimens by immunohistochemistry. The results suggest that up‐regulation of CBP during androgen ablation may be relevant to the failure of endocrine therapy in patients with prostate carcinoma. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>15378487</pmid><doi>10.1002/path.1609</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3417 |
| ispartof | The Journal of pathology, 2004-10, Vol.204 (2), p.159-166 |
| issn | 0022-3417 1096-9896 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66905713 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Aged, 80 and over androgen Androgen Antagonists - pharmacology androgen receptor Anilides - pharmacology Biological and medical sciences CBP Cell Line, Tumor co-activators CREB-Binding Protein Down-Regulation - genetics endocrine therapy Enzyme Inhibitors - pharmacology Epidermal Growth Factor - pharmacology Gene Expression Regulation, Neoplastic - genetics Gynecology. Andrology. Obstetrics Humans Immunohistochemistry - methods Insulin-Like Growth Factor I - pharmacology Interleukin-6 Investigative techniques, diagnostic techniques (general aspects) Male Male genital diseases Medical sciences Metribolone - pharmacology Nephrology. Urinary tract diseases Nitriles Nuclear Proteins - genetics Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques prostate cancer prostate cancer cell line Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Receptors, Androgen - genetics RNA, Messenger - analysis RNA, Neoplasm - analysis Tosyl Compounds Trans-Activators - genetics Tumors Tumors of the urinary system Tyrphostins - pharmacology Up-Regulation - genetics Urinary tract. Prostate gland |
| title | The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A03%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20androgen%20receptor%20co-activator%20CBP%20is%20up-regulated%20following%20androgen%20withdrawal%20and%20is%20highly%20expressed%20in%20advanced%20prostate%20cancer&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Comuzzi,%20Barbara&rft.date=2004-10&rft.volume=204&rft.issue=2&rft.spage=159&rft.epage=166&rft.pages=159-166&rft.issn=0022-3417&rft.eissn=1096-9896&rft.coden=JPTLAS&rft_id=info:doi/10.1002/path.1609&rft_dat=%3Cproquest_cross%3E66905713%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66905713&rft_id=info:pmid/15378487&rfr_iscdi=true |